Activity Preview

Live

Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA)

Activity Type:

  • On-Demand

Release Date: 4/7/2019

Expiration Date: 9/30/2019

  • CME: 1.5
  • Participation - no CE credit: 1.5

Description

In the last 12 months, landmark trials including “Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA)” and the “Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF)” have potentially changed the landscape of atrial fibrillation (AF) ablation. 

This webinar explores key outcomes from the CABANA trial, including mortality, hospitalization, stroke, arrhythmia burden and quality of life. Discussion will also include the decision-making process for selecting appropriate patients for AF ablation.

 

Support - This enduring material is supported in part by Abbott Laboratories, Biosense Webster and Medtronic.

 

Learning Objectives

  • Identify key outcomes from the CABANA trial
  • Distinguish “intention-to-treat” from “on treatment” analyses
  • Define the impact of atrial fibrillation ablation on arrhythmia burden and quality of life
  • Apply lessons from CABANA to optimize patient selection for atrial fibrillation ablation

Target Audience

  • Cardiologists
  • Electrophysiologists
  • Physicians/Fellows

Faculty

Robert Harrington, MD - Moderator
Stanford University

Doug Packer, MD
Mayo Clinic

Dan Mark, MD
Duke University Medical Center

Jeanne Poole, MD
University of Washington Medical Center

Hugh Calkins, MD
Johns Hopkins Medicine

Deepak Bhatt, MD
Brigham and Women’s Hospital

Disclosures

Faculty -
Robert Harrington, MD
Honoraria/Speaking/Consulting Fee: Element Science; Myokardia; WebMD

Doug Packer, MD
Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc.; Boston Scientific Corp.; CardioFocus, Inc.; CardioInsight Technologies; Medtronic, Inc.; Siemens; St. Jude Medical; Wiley-Blackwell; Oxford

Daniel Mark, MD
Honoraria/Speaking/Consulting Fee: CeleCor, NovoNordisk
Research (Contracted Grants for PIs and Named Investigators Only): Merck Pharmaceuticals, Oxygen Therapeutics, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals, Mayo Clinic, Eli Lilly.

Jeanne Poole, MD
Honoraria/Speaking/Consulting Fee: Kestra, Inc, Boston Scientific, EBR Systems, Medtronic, Inc.
Research (Contracted Grants for PIs and Named Investigators only): AtriCure, Inc.

Hugh Calkins, MD
Honoraria/Speaking/Consulting Fee: Abbott Laboratories, Biosense Webster, Inc., Toray Industries Inc., Boehringer Ingelheim, Boston Scientific Corp., Medtronic, Inc., Sanofi Aventis
Research (Contracted Grants for PIs and Named Investigators only): Boston Scientific Corp.

Deepak Bhata, MD
Nothing to disclose

Staff/Planners
David Frankel, MD
Honoraria/Speaking/Consulting Fee: Abbott Laboratories, Boston Scientific

Jared Bunch, MD
Research (Contracted Grants for PIs and Named Investigators only): Boston Scientific Corp., Boehringer Ingelheim.

Christine Albert, MD
Honoraria/Speaking/Consulting Fee: Myokardia; Sanofi Aventis
Research (Contracted Grants for PIs and Named Investigators only): Abbott Laboratories; Roche Diagnostics; St. Jude Medical.

Nassir Marrouche, MD
Honoraria/Speaking/Consulting Fee: Preventice; Medtronic, Inc.; Biotronik; Biosense Webster, Inc.
Research (Contracted Grants for PIs and Named Investigators only): Biosense Webster, Inc.; Abbott Laboratories; Boston Scientific

Tim Gregory
Nothing to Disclose

Jacqueline Thomas
Nothing to Disclose

Russell Werlinich
Nothing to Disclose

Support

Support - This enduring material is supported in part by Abbott Laboratories, Biosense Webster and Medtronic.

CME Information

ACCREDITATION STATEMENT
The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
The Heart Rhythm Society designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The AMA has determined that physicians not licensed in the United States who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

A Certificate of Participation (for non-physicians) will be provided to individuals seeking credit from the following organizations which accept AMA PRA Category 1 Credit(s)™. Note that participants are advised to contact their certifying body for specific information regarding credit submissions:

  • American Academy of Family Practice (AAFP) for elective credit
  • American Academy of Nurse Practitioners Certification Board (AANPCB)
  • American Academy of Physician Assistants (AAPA)
  • American Nurses Credentialing Center (ANCC)
  • American Osteopathic Association (AOA) for Category 2 credit
  • European Board of Accreditation in Cardiology (EBAC)
  • European CME Credits (ECMEC)

DISCLOSURE OF FACULTY’S COMMERCIAL RELATIONSHIP(S)

It is the policy of the Heart Rhythm Society to ensure balance, independent objectivity, and scientific rigor in all its certified educational activities. Everyone involved in the planning and participation of continuing medical education activities is required to disclose any real or apparent conflicts of interest related to the content in his/her presentation(s) and also disclose discussions of unlabeled/unapproved uses of drugs or devices during his/her presentation(s). Detailed disclosure information will be available prior to the activity and in the activity slides.

Content Development and Validation

All Heart Rhythm Society content--from objectives to content development, evaluation and measuring outcomes--is developed in compliance with ACCME guidelines. The Society’s education content is developed by expert physicians and vetted through the Education Committee to ensure alignment with organization strategic goals and that content is appropriate. Content is then reviewed by the CME Subcommittee to ensure quality and balance. HRS deploys a standard content validation form that must be signed by reviewers that states the content has been reviewed and approved.

Validation

Heart Rhythm Society takes steps to assure its learners and the public that the content of certified activities is accurate and reliable. The following principles are applied to the process of validating CME content. The content is peer- reviewed to ensure the following:

  • Fair Balance - that content is balanced among various options available for treatment and not biased toward a particular product or manufacturer.
  • Patient Treatment Recommendations - that patient treatment recommendations contained in the content are evidence-based, are appropriate for the target audience, and that the patient treatment recommendations contribute to overall improvement in patient care.
  • Scientific Validity - that scientific studies cited in the activity conform to standards accepted by the scientific community.
  • Learning Objectives - that the educational content supports the learning objectives of the activity, and that the objectives stated for performance-in-practice are actionable and measurable.
  • Omission and Commission - are there any studies, data, or best evidence that is missing?

CME Mission Statement

The Heart Rhythm Society CME Mission provides a framework for guiding and conducting the organization’s CME program and its educational activities. The CME Mission is clearly aligned with the Organizational Mission. The CME Mission Statement consists of six essential elements: purpose, scope, target audience, content, types of activities, and expected results. The purpose and scope of the Heart Rhythm Society CME Mission is to provide academically rigorous learning through the use of innovative teaching methods and advanced technologies that will enhance the ability of heart rhythm specialists worldwide to provide excellent patient care throughout their careers. The target audience is primarily heart rhythm physician specialists, but also includes scientists and other healthcare professionals who are dedicated to the study and management of heart rhythm disorders. The content covers any topic that addresses disturbances of the heart's rhythm or electrical activation, including the diagnosis, treatment, and prevention of bradyarrhythmias, tachyarrhythmias, sudden death, and cardiac dysfunction associated with electrophysiologic abnormalities. Emphasis will be placed on education designed to improve quality of life and survival for patients.

To accomplish the CME Mission, the Heart Rhythm Society currently develops the following types of educational activities:

  • Educational courses and symposia, including didactic presentations, interactive computer sessions and workshops;
  • Enduring materials, including audiotapes, CD-ROMs, and Webcasts;
  • Activities, such as those listed above, developed through collaboration with other medical organizations, in compliance with the ACCME Essentials and Standards

Expected results include improved knowledge and understanding resulting in improvements in health care provider competence, performance, or patient outcomes. Whenever possible, educational activities will be designed to address gaps in performance as compared to accepted performance measures or benchmarks determined by expert consensus and based upon scientific evidence. Evaluation of changes in behavior as a result of educational interventions will help guide future initiatives.

REPORTING CONFLICT OF INTEREST OR BIAS IN A PRESENTATION

Allegations of conflict of interest and bias are taken seriously and are investigated by the Ethics Oversight Committee, Scientific Sessions Program Committee and/or the Education Committee. Your complaint will be referred to the appropriate committee, and you will be informed in writing of the outcome of its review and decision. Submit a confidential complaint by completing the form at http://www.hrsonline.org/index.php/About-HRS/Heart-Rhythm-Society-Governance/Conflict-of-Interest-Complaint-Form  or submit an email message to education@HRSonline.org.

Access Activity